PRICE T ROWE ASSOCIATES INC /MD/ - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 162 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2013. The put-call ratio across all filers is 0.83 and the average weighting 0.3%.

Quarter-by-quarter ownership
PRICE T ROWE ASSOCIATES INC /MD/ ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q4 2018$21,000
-56.2%
105,4020.0%0.00%
Q3 2018$48,000
-9.4%
105,4020.0%0.00%
Q2 2018$53,000
-78.5%
105,402
-0.5%
0.00%
Q1 2018$247,000
+0.4%
105,958
+22.2%
0.00%
Q4 2017$246,000
-41.3%
86,702
-40.8%
0.00%
Q3 2017$419,000
+34.3%
146,352
+15.9%
0.00%
Q2 2017$312,000
-27.8%
126,252
+5.4%
0.00%
Q1 2017$432,000
+6.7%
119,752
+4.7%
0.00%
Q4 2016$405,000
-12.3%
114,3520.0%0.00%
Q3 2016$462,000
-4.5%
114,352
+3.8%
0.00%
Q2 2016$484,000
+72.2%
110,152
+48.1%
0.00%
Q1 2016$281,000
-63.6%
74,352
+51.3%
0.00%
Q4 2015$771,000
+44.1%
49,152
-3.2%
0.00%
Q3 2015$535,000
-56.8%
50,752
+3.4%
0.00%
Q2 2015$1,238,000
-2.4%
49,082
+7.8%
0.00%
Q1 2015$1,269,000
+52.7%
45,5320.0%0.00%
Q4 2014$831,000
+23.5%
45,532
-12.4%
0.00%
Q3 2014$673,000
+8.9%
51,962
+37.3%
0.00%
Q2 2014$618,000
+4.9%
37,840
+13.5%
0.00%
Q1 2014$589,000
-63.5%
33,350
-50.0%
0.00%
Q4 2013$1,614,000
+13.7%
66,700
+66.5%
0.00%
Q3 2013$1,419,000
+5.1%
40,050
-53.7%
0.00%
Q2 2013$1,350,00086,5000.00%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q4 2013
NameSharesValueWeighting ↓
Ridgeback Capital Investments L.P. 1,025,000$24,815,00031.36%
TSP Capital Management Group, LLC 836,342$20,248,0008.80%
Iguana Healthcare Management, LLC 200,000$4,842,0002.76%
First Light Asset Management, LLC 116,096$2,811,0002.38%
SECTORAL ASSET MANAGEMENT INC 2,227,688$53,932,0002.33%
BENNETT LAWRENCE MANAGEMENT L L C/NY 550,735$13,334,0002.05%
Eventide Asset Management 257,000$6,222,0001.92%
Redmile Group, LLC 397,951$9,634,0001.19%
ARDSLEY ADVISORY PARTNERS LP 357,000$8,643,0001.15%
Rhenman & Partners Asset Management AB 90,000$2,179,0000.85%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders